Stoke Therapeutics, Inc. - 10-Q Filing
Stoke Therapeutics filed its 10-Q for the quarter ended March 31, 2026, reporting a net loss of $45.2 million compared to a net loss of $38.9 million in the same period in 2025. The company reported $10.5 million in revenue, primarily from its Biogen license agreement, and research and development expenses of $34.8 million. Total cash, cash equivalents, and marketable securities were $198.4 million as of March 31, 2026.
Tickers: $STOK